Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1974 Jun;53(6):1607-17.
doi: 10.1172/JCI107711.

Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone

Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone

R J Lewis et al. J Clin Invest. 1974 Jun.

Abstract

An examination of the metabolic fate of the R and the S isomers of warfarin revealed that the two isomers were metabolized by different routes. R warfarin was oxidized to 6-hydroxywarfarin and was reduced to the (R,S) warfarin alcohol. In contrast, S warfarin was oxidized to 7-hydroxywarfarin and was reduced to the (S,S) warfarin alcohol. S warfarin was also oxidized to 6-hydroxywarfarin. These observations suggested that interactions between warfarin and other drugs might be manifest stereo-specifically, i.e., have a different effect on the isomers of warfarin, so a series of experiments were conducted with each isomer of warfarin, before and after phenylbutazone. The plasma clearance of S warfarin was slowed from 3.1 to 1.1% per h in one subject and from 2.3 to 1.6% per h in another. In contrast, the clearance of R warfarin was increased from 1.5 to 3.0% per h and from 0.9 to 1.6% per h in two subjects after phenylbutazone. The rate of clearance of racemic warfarin was unaffected by phenylbutazone; the depression of the rate of clearance of the S isomer masked the stimulation of the clearance of the R isomer. Since S warfarin is five times more potent an anticoagulant than R warfarin, it is concluded that inhibition of the metabolism of S warfarin provides one mechanism for the augmented anticoagulation which follows phenylbutazone.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 1965 Aug;149(2):272-9 - PubMed
    1. N Engl J Med. 1967 Mar 2;276(9):496-501 - PubMed
    1. Biochem Pharmacol. 1967 Jul 7;16(7):1219-26 - PubMed
    1. N Engl J Med. 1967 Oct 26;277(17):889-94 - PubMed
    1. J Med Chem. 1969 May;12(3):517-8 - PubMed